

UK Chemotherapy Board

Meeting held at 2.00pm on Wednesday 7 November 2018 at The Royal College of Radiologists

PUBLIC MINUTES

Present: Dr Jeanette Dickson (Chair, The Royal College of Radiologists (RCR))
Ms Lisa Barrott (UK Oncology Nursing Society (UKONS))
Dr Ruth Board (Royal College of Physicians (RCP))
Ms Pinkie Chambers (British Oncology Pharmacy Association (BOPA))
Dr Janine Mansi (Association of Cancer Physicians (ACP))
Dr Catherine Oakley (UKONS)
Prof Nick Reed (Scotland)
Dr Tom Roques (RCR)
Ms Edna Young (lay member)

Guests: Ms Victoria Fashina (Project Lead, SACT Regimen-Specific Consent Forms)
Dr Alice Turnbull (National Cancer Registration and Analysis Service (NCRAS), Public Health England (PHE))
Dr Achilleas Mavrellis (NCRAS, PHE)

In Attendance: Ms Gillian Dollamore (Executive Officer, Clinical Oncology, RCR)

1 Apologies, Welcome and Conflicts of Interest

Apologies for absence were received from Dr Catherine Bale, Dr Pippa Corrie, Prof Finbarr Cotter, Prof David Dodwell, Prof Jo Martin, Mr Steve Williamson and Ms Alison Shore (Committee Manager, the Royal College of Physicians).

No conflicts of interest were declared.

2 Minutes of the previous meeting

The Minutes of the meeting held on 22 June 2018 were approved without amendment.

Public Minutes had been produced from this meeting for the first time. It was agreed that Public Minutes should continue to be produced from meetings of the UKCB, to promote a wider understanding of its role and activities.

3 Matters Arising

3.1 Good Practice Guide for Immuno-Oncology Medicines

Subject to a small number of minor amendments, UKCB members approved a final draft of a *Good Practice Guideline for Immuno-Oncology Medicines*. This would now be published by the Board, pending confirmation of agreement by UKONS, and would be circulated to all Trusts and Health Boards in the UK that delivered systemic anti-cancer therapies.

3.2 Cancer Patient Treatment Record

Following discussion at the previous meeting, CRUK had amended the draft of a new Cancer Patient Treatment Record. This would be published in time for launch at the UKONS annual conference on 16-17 November 2018. It would not yet be available in electronic format but hard copies could be ordered from [Cancer Research UK](#). It was intended that an App might be available in due course.

3.3 Acute Oncology Initial Management Guidelines

The final version of these guidelines had been produced in the summer. The UKCB was awaiting agreement by all professional body members of the UKCB for their logos to be added to this document to indicate their support.

3.4 Cancer Treatments and Sepsis

UKCB members had previously commented on a draft of a patient leaflet on cancer treatments and sepsis. The final version would be published in mid-November.

4 Chemotherapy Board Workstreams

4.1 Chemotherapy Consent Forms – update

The UKCB received an update on progress with the project to develop national regimen-specific SACT consent forms. Seventy seven consent forms were published in year 3 of the project, bringing the total number of forms to 229. Two groups of forms had yet to be completed – for skin non-melanoma and for neuro-endocrine and adrenocortical cancers.

A survey of uptake of the SACT consent forms in 2018 indicated that an increasing number of hospitals were now using the forms. Feedback on the forms was generally positive although some concerns were expressed about the length of the forms, some operational processes in their use and the non-availability of forms for paediatric and haematological cancers.

The National Steering Group for the SACT consent forms project had met for the first time in July and would continue to report to the UKCB as the governing body for the SACT consent forms.

4.2 Age is no Barrier to Chemotherapy

The results of this project had been submitted to *Lancet Oncology* for publication. There were plans for a more in-depth analysis of three tumour groups in breast, colon and lung cancers.

4.3 Chemotherapy Workforce

The UKCB had published a statement on the non-surgical cancer treatment workforce. This had been sent to the Chief Executive of Health Education England (HEE) and a response had been received.

UKCB members noted the ongoing work by both HEE and NHS England on the cancer workforce and the importance of ensuring that this addressed all professionals within the non-surgical cancer treatment workforce, including non-medical prescribers and oncology pharmacists. Workforce remained a key priority for the UKCB.

5 Proposal for collaborative Neutropenic Sepsis information ‘bundle’ launch 2019

The UKCB agreed its support for collaborative working by a number of key stakeholders to produce and launch a national resource on sepsis. The intention behind this was to standardise care and promote risk-stratification.

6 Chemotherapy Data

6.1 SACT Dataset update

UKCB members received a presentation from Dr Alice Turnbull about the ongoing collection, analysis and reporting of SACT Data in England. They welcomed the progress being made not only with SACT data collection but also with plans for national reporting.

7 Items for report

7.1 Chemotherapy E-learning Modules

E-learning modules on understanding and prescribing chemotherapy that had been developed by Guy's and St Thomas' NHS Foundation Trust were now available through the King's Health Partners' new [Learning Hub](#).

7.2 Continuation of funding for chemotherapy following break in treatment

The UKCB discussed the NHS England Specialised Services Circular 1918, published in August, on rules around treatment breaks. A number of concerns had been raised about the implications of these rules both for patients and for treating clinicians. The UKCB agreed to raise these concerns in the first instance with the NHS England Chemotherapy Clinical Reference Group.

7.3 Diabetes and hepatitis infections in cancer chemotherapy patients

UKCB members noted the recommendation issued by the National Institute for Health and Care Excellence (NICE) on screening of all cancer patients for Hepatitis B prior to treatment, unless very low risk. The Board was considering whether or not to issue a statement to promote and raise awareness of this recommendation.

Board members also considered the possible need for national guidance on screening of cancer patients for diabetes. However, as this condition was so prevalent, a recommendation for routine screening would be a significant undertaking.

8 Chemotherapy Commissioning

8.1 Update from Chemotherapy Clinical Reference Group

The UKCB noted two recent stakeholder consultations issued by the CRG relating to draft Clinical Commissioning policy statements for Pazopanib for inoperable and metastatic malignant granular tumours and Bendamustine for relapsed/refractory classical Hodgkin lymphoma.

8.2 Update from the Acute Oncology Sub-Group

The UKCB received an update on the work of the Acute Oncology (AO) Sub-Group of the Chemotherapy CRG.

9 Commissioning Chemotherapy Services conference, 6 December 2018

The 2018 Commissioning Chemotherapy Services conference would take place on Thursday 6 December and would, for the first time, be hosted by the UKCB.

10 Dates of Meetings in 2019

The dates of the meetings of the UKCB in 2019 were confirmed as Monday 14 January, Thursday 6 June and Monday 7 October. Chairmanship and administration of the Board would pass to Dr Board and the RCP (jointly with the ACP) on 1 January 2019.